Britannia Pharmaceuticals has promoted Robert Wood to marketing director, for international markets.
Wood was previously director partners, EMEA at Britannia and has 15 years experience in the life science and pharmaceutical industries.
Prior to joining Britannia, which is part of Stada, in early 2011, his roles included business unit director, pharmaceuticals at International SOS and vice president of business development at Optasia Medical.
Britannia Pharmaceuticals has been working in Parkinson’s disease for over thirty years and its APO-go product range is licensed in almost 40 countries.
Wood said: “I am delighted to be continuing to work with Britannia Pharmaceuticals in this new global role, particularly at this incredibly interesting time for the APO-go therapy.
“The initiation of clinical trials to increase the evidence base for both motor and non-motor effects of APO-go in Parkinson’s disease and the development of new delivery devices, mean APO-go will provide an excellent treatment option for many more people with Parkinson’s.”